ClinicalTrials.gg
Not yet recruitingNCT07124403DESIRUpdated Nov 2, 2026

DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure

An observational study in Renal Impairment, Digestive Cancers and Breast Cancer, sponsored by Centre Hospitalier Universitaire de Besancon. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
742
Ages
18 Years and older
Sex
All
01

Study summary

Fluoropyrimidine drugs (5-Fluorouracil or 5-FU and its prodrug capecitabine) are a widely used in the treatment of numerous solid tumors in adults. Approximately 85% of administered 5-FU is rapidly catabolized in the liver into inactive dihydrofluorouracil (5-FUH2) by dihydro-pyrimidine dehydrogenase (DPD), leaving only a small fraction of the initial drug for an eventual transformation into cytotoxic metabolites. Impeded DPD activity is associated to an increase of cytotoxic metabolites leading to potentially very severe toxicities.

To prevent these toxicities, a pre-therapeutic measurement of plasma uracil can help assess DPD activity. Indeed, uracil is an endogenous substrate of DPD and an increase in its plasma concentration may be associated with a decrease in DPD activity. In this case, a reduction of the fluoropyrimidine dose is suggested.

However, the investigators observed that uracilemia increased concomitantly to the severity of renal impairment. There are two possible explanations for this observation. Either the renal impairment reduces the renal elimination of uracil from blood, or DPD activity is actually impaired. In both cases, this can explain an increase in plasma uracil concentration.

However, the impact on fluoropyrimidine dosage is different in the two cases. If the increase in uracilemia is due to renal impairment, DPD activity remains unaffected and there is no need to reduce the fluoropyrimidine dose. If DPD activity is actually impaired, a reduction in the fluoropyrimidine dose is required. In cases of renal impairment, uracilemia may therefore not be as relevant for DPD assessment as in the absence of renal impairment.

To assess if DPD activity is actually impede during renal impairment, the DPD activity of Peripheral Blood Mononuclear Cells (PBMCs) will be assessed together with uracilemia in patients with or without renal impairment. As uracilemia decreases after dialysis, the DPD activity of Peripheral Blood Mononuclear Cells (PBMCs) will also be assessed in patient before and after dialysis. Four groups of 50 patients will be studied: patients with normal renal function with hyperuracilemia (uracilemia ≥ 16 ng/mL) or normal uracilemia (uracilemia \< 16 ng/mL) ; and patients with renal impairment with hyperuracilemia (uracilemia ≥ 16 ng/mL) or normal uracilemia (uracilemia \< 16 ng/mL).

The main objective of the study is to describe the distribution of DPD activity in these four populations. The secondary objectives are to determine in normorenal patients the optimal threshold for DPD activity in non-deficient patients, allowing differentiation between deficient and non-deficient patients based on uracilemia ; and to describe in patients with impaired renal function the distribution of uracilemia with respect to the threshold previously described with the aim of verifying the relevance of uracilemia as a marker of DPD activity in such patients.

02

Conditions studied

  • Renal Impairment
  • Digestive Cancers
  • Breast Cancer
03

In context

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

This study's planned enrollment of 742 is above the median of 178 across 294 observational studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with breast or digestive cancer patients on dialysis patients with IR

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Affiliation to the Social Security System
  • Patients with breast or digestive cancer for whom a fluoroptmidine therapy is being considered
  • OR Patients on dialysis ( \< 10 ml/min/1.73 m²)
  • OR Nephrology patients with IR

Exclusion criteria

Exclusion Criteria:

  • Patient with anemia \< 8.5 g/dl
  • Patient with LDH > 2 x >
  • Legal incapacity or limited legal capacity
  • Subject without health insurance
  • Subject in the exclusion period of another study or in the "national volunteer file"
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
742 participants (estimated)
Patient registry
No

Groups and cohorts

  • PATIENT WITH SOLID TUMOR OR RENAL IMPAIRMENT

    Diagnostic Test: blood sampling

Interventions

  • Diagnostic testblood sampling

    DPD Activity wil be assessed from blood samples

  • Diagnostic testBlood sampling

    Measurement of uracilemia and assessment of renal function

06

What researchers measure

Primary outcomes

  1. DPD Activity measurement in blood

    DPD Activity is assessed in PBMC in µmole of 5FUH2 / h / 1 million cells

    Time frame: 3 years

  2. Uracilemia in plasma

    Uracilemia will be measured in plasma in µg/L

    Time frame: 3 years

  3. uracilemia-based DPD activity measurement

    differentiation between deficient and non-deficient patients will be based on uracilemia (\<16, ≥16)

    Time frame: 3 years

  4. assessment of renal function using eGFR

    eGFR is expressed in ml/min/1.73m²

    Time frame: 3 years

  5. sex

    M/F used for eGFR calculation

    Time frame: 3 years

  6. Age

    Years, used for eGFR calculation

    Time frame: 3 years

  7. creatininemia

    µmol/l, used for eGFR calculation

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2027; primary completion for Mar 2029, 17 months later.

Of 88 non-industry observational studies under Renal Insufficiency, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 17 months is below that.

Counting every sponsor, half of 103 studies reached it within 30 months; a quarter within 14 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Sep 2025 → Oct 2027, primary completion Mar 2028 → Mar 2029 and completion Sep 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Aug 15, 2025
StartEst.
Oct 2027was Sep 2025
Primary completionEst.
Mar 2029was Mar 2028
CompletionEst.
Sep 2029was Sep 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2025→Oct 2027
Nov 2, 2026
Primary completion
Mar 2028→Mar 2029
Nov 2, 2026
Study completion
Sep 2028→Sep 2029
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Sep 2025→Oct 2027
    Primary completion Mar 2028→Mar 2029
    Study completion Sep 2028→Sep 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07124403
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Oct 2027 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion